Structure-activity relationship of quinoline derivatives as potent and selective α2c-adrenoceptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 21, 2006, Pages 6351-6363

  Höglund, Iisa P J ^a,b   Silver, Satu ^a   Engström, Mia T ^a   Salo, Harri ^a,b   Tauber, Andrei ^a,c   Kyyrönen, Hanna Kaisa ^a,d   Saarenketo, Pauli ^a,e   Hoffrén, Anna Marja ^a,f   Kokko, Kurt ^a,g   Pohjanoksa, Katariina ^a   Sallinen, Jukka ^a,b   Savola, Juha Matti ^a   Wurster, Siegfried ^a   Kallatsa, Oili A ^a  

^a Oy Juvantia Pharma Ltd   (Finland)

^b ORION CORPORATION   (Finland)

^c KEMIRA OYJ   (Finland)

^d Astra Zeneca Oy   (Finland)

^e Employment Economic Devmt Ctr C   (Finland)

^f FBD Ltd   (Finland)

^g National Bureau of Investigation Finland   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [4 (3,4 DIMETHYLPIPERAZIN 1 YL)PHENYLAMINO]QUINOLIN 3 YL]METHANOL; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ALPHA2C ADRENERGIC RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; AMINOQUINOLINES; ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CRICETINAE; CRICETULUS; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MICE; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, ALPHA-2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750126094     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060262x     Document Type: Article

References (35)

1. 2-Adrenergic Receptors. Structure, Function and Therapeutic Implications; Lanier, S. M., Limbird, L. E., Eds.; Overseas Publishers Association: Amsterdam, 1997; pp 1-18.
2. MacDonald, E.; Kobilka, B. K.; Scheinin, M. Gene targeting-homing in on α2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 1997, 18, 211-219.
3. Scheinin, M.; Lomasney, J. W.; Hayden-Hixson, D. M.; Schambra, U. B.; Caron, M. G.; Lefkowitz, R. J.; Fremeau, R. T., Jr. Distribution of alpha2-adrenergic receptor subtype gene expression in rat brain. Brain Res. Mol. Brain Res. 1994, 21, 133-149.
4. 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J. Comp. Neurol. 1996, 372, 135-165.
5. Scheinin, M.; Sallinen, J.; Haapalinna, A. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci. 2001, 68, 2277-2285.
6. Brede, M.; Philipp, M.; Knaus, A.; Muthig, V.; Hein, L. Alpha2-adrenergic receptor subtypes-novel functions uncovered in gene-targeted mouse models. Biol. Cell 2004, 96, 343-348.
7. Kalkman, H. O.; Loetscher, E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur. J. Pharmacol. 2003, 462, 33-40.
8. Arnsten, A. F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berlin) 2004, 174, 25-31.
9. Mayer, P.; Imbert, T. Alpha2-Adrenoreceptor antagonists. IDrugs 2001, 4, 662-676.
10. 2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiat. 1999, 4, 443-452.
11. Petit-Demouliere, B.; Chenu, F.; Bourin, M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berlin) 2005, 177, 245-255.
12. Swerdlow, N. R.; Braff, D. L.; Taaid, N.; Geyer, M. A. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiat. 1994, 57, 139-154.
13. 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J. Neurosci. 1998, 18, 3035-3042.
14. Wurster, S.; Engström, M.; Savola, J.-M.; Höglund, I.; Sallinen, J.; Haapalinna, A.; Tauber, A.; Hoffren, A.-M.; Salo, H. Derivatives of quinoline as alpha-2 antagonists. Patent WO 0164645, 2001.
15. Roland, S.; Mangeney, P.; Alexakis, A. A practical and efficient synthesis of enantiomerically pure di-tert-butyl-ethanediamine. Synthesis 1999, 228-230.
16. Cain, B. F.; Atwell, G. J.; Denny, W. A. Potential antitumor agents. 23, 4′-(9-acridinylamino)alkanesulfonamide congeners bearing hydrophilic functionality. J. Med. Chem. 1977, 20, 987-996.
17. Conrad, M.; Limpach, L. Synthesen von Chinolin derivativen mittelst Acetessigester. Ber. Dtsch. Chem. Ges. 1887, 20, 944.
18. Gould, R. G.; Jacobs, W. A. The synthesis of certain substituted quinolines and 5,6-benzoquinolines. J. Am. Chem. Soc. 1939, 61, 2890-2895.
19. Cain, B. F.; Seeyle, R. N.; Atwell, G. J. Potential antitumor agents. 14. Acridylmethanesulfonanilides. J. Med. Chem. 1974, 17, 922-930.
20. Steck, E. A.; Hallock, L. L.; Holland, A. J.; Quinolines, I. The synthesis of 3-methyl-4-(1′-methyl-4′-diethylaminobutylamino)- quinoline and some 6-substituted derivatives. J. Am. Chem. Soc. 1946, 68, 129-132.
21. Gildemeister, H.; Knorr, H.; Mildenberger, H.; Salbeck, G. Neue 4-Chinolinol- und 5,6,7,8-Tetrahydro-4-chinolinolabkömmlinge mit biozider Wirkung. Liebigs Ann. Chem. 1982, 1656-1676.
22. Ackermann, O.; Bleh, O.; Regler, W. Method of preparing alkoxy-methylenemalonic acid esters. U.S. Patent 4058553, 1977.
23. Zoghbi, M., Chen, L. Synthesis of pharmaceutically useful pyridine derivatives. U.S. Patent 6437139, 2002.
24. Neuville, L.; Zhu, J. Solution phase combinatorial synthesis of arylpiperazines. Tetrahedron Lett. 1997, 38, 4091-4094.
25. Godek, D. M.; Murtiashaw, C. W.; Urban, F. J.; Vanderplas, B. C. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents. U.S. Patent 5455350, 1995.
26. Mickelson, J. W.; Belonga, K. L.; Jacobsen, E. J. Asymmetric synthesis of 2,6-methylated piperazines. J. Org. Chem. 1995, 60, 4177-4183.
27. Moore, M. L. The Leuckart Reaction. In Organic Reactions; John Wiley & Sons Inc.: New York, 1949; Vol. V, Chapt. 7, pp 301-323
28. Su, T.-L.; Chen, C.-H.; Huang, L.-F.; Chen, C.-H.; Basu, M. K.; Zhang, X.-G.; Chou, T.-C. Synthesis and structure-activity relationships of potential anticancer agents: Alkylcarbamates of 3-(9-acridinylamino)-5- hydroxymethylaniline. J. Med. Chem. 1999, 42, 4741-4748.
29. Chen, Y.-L.; Lu, C-M.; Chen, I.-L.; Tsao, L.-T.; Wang, J.-P. Synthesis and antiinflammatory evaluation of 9-anilinoacridine and 9-phenoxyacridine derivatives. J. Med. Chem. 2002, 45, 4689-4694.
30. Finlay, G. J.; Riou, J.-F.; Baguley, B. C. From Amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer 1996, 32A, 708-714.
31. Wang, L.; Price, H. L.; Juusola, J.; Kline, M.; Phanstiel IV, O. Influence of polyamine architecture on the transport and topoisomerase II inhibitory properties of polyamine DNA-intercalator conjugates. J. Med. Chem. 2001, 44, 3682-3691.
32. Marjamäki, A.; Luomala, K.; Ala-Uotila, S.; Scheinin, M. Use of recombinant human alpha 2-adrenoceptors to characterize subtype selectively of antagonist binding. Eur. J. Pharmacol. 1993, 246, 219-226.
33. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
34. Jasper, J. R.; Lesnick, J. D.; Chang, L. K.; Yamanishi, S. S.; Chang, T. K.; Hsu, S. A.; Daunt, D. A.; Bonhaus, D. W.; Eglen, R. M. Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem. Pharmacol. 1998, 55, 1035-1043.
35. Pohjanoksa, K.; Jansson, C. C.; Luomala, K.; Marjamaki, A.; Savola, J.-M.; Scheinin, M. Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur. J. Pharmacol. 1997, 335, 53-63.